切换至 "中华医学电子期刊资源库"

中华眼科医学杂志(电子版) ›› 2022, Vol. 12 ›› Issue (05) : 316 -320. doi: 10.3877/cma.j.issn.2095-2007.2022.05.011

综述

硒制剂在甲状腺相关性眼病治疗中的研究进展
张鹏1, 张朝霞2, 闫春芳3, 孙斌3,()   
  1. 1. 030001 太原,山西医科大学第一临床医学院2019级硕士研究生
    2. 030002 太原,山西省眼科医院眼底病科 眼科学山西省重点实验室
    3. 030002 太原,山西省眼科医院眼眶病科
  • 收稿日期:2021-12-27 出版日期:2022-10-28
  • 通信作者: 孙斌
  • 基金资助:
    山西省中医药管理局传承创新项目(2020ZYYC059); 山西省医学重点科研项目(2020XM07); 眼科学山西省重点实验室培育项目(2020SYS12)

Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy

Peng Zhang1, Zhaoxia Zhang2, Chunfang Yan3, Bin Sun3,()   

  1. 1. Master′s degree 2019, First Clinical Colleage of Shanxi Medical University, Taiyuan 030001, China
    2. Department of Fundus, Shanxi Eye Hospital, Shanxi Province Key Laborary of Ophthalmology, Taiyuan 030002, China
    3. Department of Orbital Ophthalmology, Shanxi Eye Hospital, Taiyuan 030002, China
  • Received:2021-12-27 Published:2022-10-28
  • Corresponding author: Bin Sun
引用本文:

张鹏, 张朝霞, 闫春芳, 孙斌. 硒制剂在甲状腺相关性眼病治疗中的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2022, 12(05): 316-320.

Peng Zhang, Zhaoxia Zhang, Chunfang Yan, Bin Sun. Research progress of selenium preparation in the treatment of thyroid associated ophthalmopathy[J/OL]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(05): 316-320.

甲状腺相关性眼病(TAO)是与自身免疫性甲状腺疾病相关的器官特异性自身免疫性疾病,在成人眼眶病中居首位。硒是人体必不可少的生物微量元素,以硒蛋白质的形式维持机体功能。有研究结果表明,硒对轻度活动性TAO具有疗效;同时,欧洲Graves眼病诊疗指南推荐对早期轻度患者给予硒制剂治疗,改善眼部症状,提高患者的生活质量,防止疾病恶化。但目前其机制尚不明确。因此,本文中笔者就硒制剂在TAO诊疗中作用机制、应用及其前景的研究进展进行综述。

Thyroid associated ophthalmopathy (TAO) is an organ specific autoimmune disease related to autoimmune thyroid disease, which ranks first in adult orbital disease. Selenium is an essential biological trace element in human body, which maintains the body function through the action of selenium protein. It has demonstrated that selenium has a certain effect on mild active TAO. At the same time, the European Graves′ ophthalmopathy collaborative group on Graves orbitopathy clinical practice guidlines recommend that the early mild TAO patients should be treated with selenium, which can improve the eye symptoms, the quality of life and prevent the disease from escalating. However, its mechanism is still unclear. Based on these, the treatment mechanism, application and its prospect of selenium preparation in TAO were reviewed.

图1 眶周组织与甲状腺的共同抗原学说示意图
[1]
邵毅,陈偲翊,廖许琳. 2019甲状腺相关性眼病管理实用指南解读[J]. 国际眼科杂志202121(8):1408-1411.
[2]
Kieliszek M. Selenium fascinating microelement, properties and sources in food[J]. Molecules, 2019, 24(7): 1318-1322.
[3]
Gontarz-Nowak K, Szychlińska M, Matuszewski W, et al. Current knowledge on Graves′ orbitopathy[J]. J Clin Med, 2020, 10(1): 30-32.
[4]
姬璇,张朝霞,闫春芳,等. 甲状腺相关性眼病氧化应激反应的研究进展[J/OL]. 中华眼科医学杂志(电子版)202111(2):124-128.
[5]
Nessel TA, Gupta V. Selenium[M]. Treasure Island (FL) : StatPearls, 2021.
[6]
Lumyongsatien M, Bhaktikamala U, Thongtong P, et al. Relative selenium insufficiency is a risk factor for developing severe Graves′ orbitopathy: a case-control study[J]. BMJ Open Ophthalmol, 2021, 6(1): e000713.
[7]
Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: molecular pathways and physiological roles[J]. Physiol Rev, 2014, 94(3): 739-777.
[8]
Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases[J]. Endocr Rev, 2002, 23(1): 38-89.
[9]
易春峰,李元红. 硒预防心血管病的研究进展[J]. 中国老年学杂志201535(12):3470-3471.
[10]
Wu Q, Rayman MP, Lv H, et al. Low Population Selenium Status Is Associated With Increased Prevalence of Thyroid Disease[J]. J Clin Endocrinol Metab, 2015, 100(11): 4037-4047.
[11]
Bülow PI, Knudsen N, Carlé A, et al. Serum selenium is low in newly diagnosed Graves′ disease: a population-based study[J]. Clin Endocrinol (Oxf), 2013, 79(4): 584-590.
[12]
Wertenbruch T, Willenberg HS, Sagert C, et al. Serum selenium levels in patients with remission and relapse of graves′ disease[J]. J Med Chem, 2007, 3(3): 281-284.
[13]
Arikan TA. Plasma selenium levels in first trimester pregnant women with hyperthyroidism and the relationship with thyroid hormone status[J]. Biol Trace Elem Res, 2015, 167(2): 194-199.
[14]
Wang W, Mao J, Zhao J, et al. Decreased thyroid peroxidase antibody titer in response to selenium supplementation in autoimmune thyroiditis and the influence of a selenoprotein P gene polymorphism: a prospective, multicenter study in China[J]. Thyroid, 2018, 28(12): 1674-1681.
[15]
Qiu Y, Xing Z, Xiang Q, et al. Insufficient evidence to support the clinical efficacy of selenium supplementation for patients with chronic autoimmune thyroiditis[J]. Endocrine, 2021, 73(2): 384-397.
[16]
Winther KH, Rayman MP, Bonnema SJ, et al. Selenium in thyroid disorders——Essential knowledge for clinicians[J]. Nat Rev Endocrinol, 2020, 16(3): 165-176.
[17]
Khong JJ, Goldstein RF, Sanders KM, et al. Serum selenium status in Graves′ disease with and without orbitopathy: a case-control study[J]. Clin Endocrinol, 2014, 80(6): 905-910.
[18]
Duntas LH, Benvenga S. Selenium: an element for life[J]. Endocrine, 2015, 48(3): 756-775.
[19]
Marinò M, Menconi F, Dottore GR, et al. Selenium in Graves hyperthyroidism and orbitopathy[J]. Ophthalmic Plast Reconstr Surg, 2018, 34(4S1): S105-S110.
[20]
Shreenath AP, Ameer MA, Dooley J. Selenium deficiency[M]. Treasure Island (FL) : StatPearls, 2021.
[21]
Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild Graves′ orbitopathy[J]. N Engl J Med, 2011, 364(20): 1920-1931.
[22]
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the Management of Graves′ Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.
[23]
朴司晨. 硒干预轻、中度Graves眼病的安慰剂对照临床研究[D]. 北京:中国医科大学,2017.
[24]
肖新怀,陈澍,苏丽芳. 硒辅助治疗Graves病伴轻度突眼的临床疗效[J]. 中国现代医学杂志201727(11):91-94.
[25]
张祎,张险峰,韩辉,等. 中小剂量甲泼尼龙联合甲氨蝶呤与硒酵母对Graves眼病的疗效观察[J]. 中华内分泌代谢杂志201625(1):24-26.
[26]
柴佩韦. 硒补充疗法对甲状腺相关眼病治疗机制的研究进展[J]. 中华实验眼科杂志201735(9):857-861.
[27]
Marinò M, Dottore GR, Leo M, et al. Mechanistic pathways of selenium in the treatment of Graves′ disease and Graves′ orbitopathy[J]. Horm Metab Res, 2018, 50(12): 887-893.
[28]
Lanzolla G, Marcocci C, Marinò M. Antioxidant therapy in Graves′ orbitopathy[J]. Front Endocrinol (Lausanne), 2020, 11: 608733.
[29]
Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves′ hyperthyroidism and eye disease[J]. Front Endocrinol (Lausanne), 2020, 11: 608428.
[30]
Kieliszek M, Baejak S. Current knowledge on the importance of selenium in food for living organisms: a review[J]. Molecules (Basel, Switzerland), 2016, 21(5): 451-456.
[31]
ZarkoviĉM. The role of oxidative stress on the pathogenesis of graves′ disease[J]. J Thyroid Res, 2012: 302537.
[32]
Hasani M, Djalalinia S, Khazdooz M, et al. Effect of selenium supplementation on antioxidant markers: a systematic review and meta-analysis of randomized controlled trials[J]. Hormones (Athens), 2019, 18(4): 451-462.
[33]
Fernández-Lázaro D, Fernandez-Lazaro CI, Mielgo-Ayuso J, et al. The role of selenium mineral trace element in exercise: antioxidant defense system, muscle performance, hormone response, and athletic performance: a systematic review[J]. Nutrients, 2020, 12(6): 1790.
[34]
Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities[J]. Antioxid Redox Signal, 2012, 16(7): 705-743.
[35]
Rotondo DG, Leo M, Casini G, et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves′ orbitopathy[J]. Thyroid, 2017, 27(2): 271-278.
[36]
张方华,阎胜利,余霄龙,等. 亚硒酸钠对体外培养人甲状腺细胞氧化损伤的影响[J]. 免疫学杂志200824(2):139-141.
[37]
Tamura T, Stadtman TC. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity[J]. Proc Natl Acad Sci U S A, 1996, 93(3): 1006-1011.
[38]
张辉,刘明法,李少臣,等. 硒和蛋白质对大鼠心肌形态结构及谷胱甘肽过氧化物酶和线粒体型硫氧还蛋白还原酶表达的影响[J]. 中国地方病学杂志201231(1):40-45.
[39]
何志伟,胡欣,陈国芳,等. 甲状腺相关性眼病病因、发病机制及免疫靶向治疗的研究进展[J]. 山东医药202060(28):90-93.
[40]
Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J]. Invest Ophth Vis Sci, 2014, 55(3): 1735-1748.
[41]
Bahn RS. Current insights into the pathogenesis of Graves′ ophthalmopathy[J]. Horm Metab Res, 2015, 47(10): 773-778.
[42]
Lantz M, Planck T, Asman P, et al. Increased TRAb and/or low anti-TPO titers at diagnosis of graves′ disease are associated with an increased risk of developing ophthalmopathy after onset[J]. Exp Clin Endocrinol Diabetes, 2014, 122(2): 113-117.
[43]
Xu B, Wu D, Ying H, et al. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves′ disease[J]. Turk J Med Sci, 2019, 49(3): 715-722.
[44]
Wichman J, Winther KH, Bonnema SJ, et al. Selenium Supplementation significantly reduces thyroid autoantibody levels in patients with chronic autoimmune thyroiditis: a systematic review and meta-analysis[J]. Thyroid, 2016, 26(12): 1681-1692.
[45]
Hai YP, Lee ACH, Frommer L, et al. Immunohistochemical analysis of human orbital tissue in Graves′ orbitopathy[J]. J Endocrinol Invest, 2020, 43(2): 123-137.
[46]
Balázs C, Kaczur V. Effect of selenium on HLA-DR EXPRESSION OF Thyrocytes[J]. Autoimmune Dis, 2012: 374635.
[47]
Shrimali RK, Irons RD, Carlson BA, et al. Selenoproteins mediate T cell immunity through an antioxidant mechanism[J]. J Biol Chem, 2008, 283(29): 20181-20185.
[48]
Tinkov AA, Ajsuvakova OP, Filippini T, et al. Selenium and selenoproteins in adipose tissue physiology and obesity[J]. Biomolecules, 2020, 10(4): 658.
[49]
Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves′ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves′ orbitopathy[J]. Eur J Endocrinol, 2021, 185(4): G43-G67.
[50]
中国营养学会. 最新中国居民膳食营养素参考摄入量要点精编[J]. 健康指南:中老年201628(11):32-33.
[51]
Rayman MP. Selenium and human health[J]. Lancet, 2012, 379(9822): 1256-1268.
[52]
乔晶. Graves眼病患者血清外泌体miRNA表达谱的差异性分析及硒干预对其远期预后影响的前瞻队列研究[D]. 北京:中国医科大学,2021.
[53]
王英爽,王雅文,张新玮. 眼眶减压术联合硒酵母片治疗对Graves伴突眼症患者疗效及对TSH、HA水平的影响[J]. 湖南师范大学学报(医学版)20207(1):158-161.
[54]
李丹丹,刘扬,元荣荣,等. 硒酵母联合甲巯咪唑治疗Graves病伴轻度突眼的临床效果[J]. 河南医学研究202029(2):217-220.
[55]
Almanza-Monterrubio M, Garnica-Hayashi L, Dávila-Camargo A, et al. Oral selenium improved the disease activity in patients with mild Graves′ orbitopathy[J]. J Fr Ophtalmol, 2021, 44(5): 643-651.
[1] 鲁梦远, 赵学刚, 郝嘉文, 盖晨阳, 李聪颖, 张晶, 张庆富. 高压电烧伤大鼠肝脏氧化应激损伤及灯盏花素的干预作用[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(02): 113-118.
[2] 杨文飞, 郝嘉文, 鲁梦远, 赵学刚, 李聪颖, 盖晨阳, 张晶, 张庆富. 高压电烧伤对大鼠心肌氧化应激的影响及N-乙酰半胱氨酸的干预作用[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(02): 106-112.
[3] 李嘉兴, 孙乙文, 李文星. NLRP3炎性小体在急性胰腺炎中作用的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 300-304.
[4] 张璇, 高杨, 房雅君, 姚艳玲. 保护性机械通气在肺癌胸腔镜肺段切除术中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 563-567.
[5] 殷国青, 曾莉, 贺斌峰, 孙芬芬. Rab26负性调控Nrf2增强肺癌耐药细胞对奥希替尼的敏感性[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 349-355.
[6] 王娟, 刘晔, 熊威, 蒋财磊, 贺燕, 叶青松. 间充质干细胞缓解阿尔茨海默病氧化应激的新思路[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 93-106.
[7] 裴捷, 毛本亮, 郝定盈, 苑伟, 颜勇, 吴帆, 王鹏珍, 王百林. 槲皮素调控肝缺血-再灌注损伤的研究进展及应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 244-249.
[8] 杜霞, 马梦青, 曹长春. 造影剂诱导的急性肾损伤的发病机制及干预靶点研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 279-282.
[9] 李佳曦, 刘子源, 李学民. 二甲双胍对年龄相关性白内障影响的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(04): 252-256.
[10] 王子琪, 李萍, 蔡标, 杨秀敏. 雌激素在糖尿病性视网膜病变中作用机制的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(03): 187-192.
[11] 李京, 牛博, 刘晓蓓, 魏新雪, 黄荣. circ-SESN2 沉默靶向调控miRNA-23a-5p/ULK1 在神经细胞氧化应激损伤中的作用机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 263-272.
[12] 冯铭, 孙洪涛. 动脉瘤性蛛网膜下腔出血的颅内压监测与管理[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 248-253.
[13] 张晟豪, 周杰, 姚鹏飞, 李长栋, 屈晓东, 南亚强, 曹丽. 雷公藤红素在创伤性脑损伤后继发性损伤中的作用及机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 132-140.
[14] 王丽丽, 张春霞, 申磊, 吴立娜, 潘青, 冯雪. 吗替麦考酚酯联合雷公藤多苷及糖皮质激素治疗对IgA肾病患者肾功能、炎症因子和氧化应激的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1285-1290.
[15] 买买提·依斯热依力, 尹强, 尹海龙, 李治建, 董雨微, 王永康, 克力木·阿不都热依木, 阿吉艾克拜尔·艾萨. 罗乐胃蜜膏抑制酸刺激诱导食管上皮细胞炎症发生的机制研究[J/OL]. 中华胃食管反流病电子杂志, 2024, 11(03): 137-142.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?